These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-004137-18 FIRM-ACT 2014-01-02 due-trials
Completed, but no date, and reported results Terminated 2006-001108-35 CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY bad-data
Not reported 2006-001353-96 Wirksamkeit eines Elterntrainings zur Behandlung der Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern in Abhängigkeit von der Behandlung ihrer ebenfalls betroffenen Mütter mit ent... 2012-05-31 due-trials
Reported results 2007-001165-15 Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC) 2012-02-10 due-trials
Ongoing, reported early 2007-004528-19 Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol® not-yet-due
Reported results 2007-006606-16 The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification regulation (fetuin-A levels) in CKD stage 5D patients 2011-03-28 due-trials
Reported results 2007-006609-25 Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients 2014-09-02 due-trials
Completed, but no date, and reported results 2008-000007-28 Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A... bad-data
Ongoing 2008-001291-71 Electrophysiological correlates of putative endophenotypes of attention-deficit / hyperactivity disorder (ADHD) not-yet-due
Reported results Terminated 2008-001686-28 Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma 2012-10-19 due-trials
Reported results 2008-006242-26 Genetic modulation of functional brain activity of attention-deficit/hyperactivity disorder-related working memory processes 2012-12-31 due-trials
Ongoing 2009-015159-26 UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients. not-yet-due
Completed, but no date, and reported results Terminated 2009-015600-26 An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with c... bad-data
Not reported 2009-016616-21 Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lena... 2023-05-26 due-trials
Completed, but no date, and reported results 2010-019415-38 A prospective, bicentric, randomised, primarily double blind, placebo-controlled study to evaluate the efficacy of zoledronic acid for the treatment of bone marrow syndrome bad-data
Reported results 2011-002687-25 Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency (PHYSCA-Trial) Pharmakokinetik der subkutanen Hydrocortis... 2012-07-13 due-trials
Completed, but no date, and reported results 2011-003179-12 Mineralocorticoid Receptor antagonists in End stage reNal DiseAse bad-data
Reported results 2013-004881-33 Pharmacovigilance in children and adolescents: clinical trial protocol, subproject 1: Large Simple Trial, IIIb on the (off-label-) use of antidepressants and antipsychotics Pharmakovigilanz in der... 2018-12-31 due-trials
Exempt 2014-003171-39 Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation not-yet-due
Exempt, with results 2015-001522-41 Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications 2021-08-23 not-yet-due
Ongoing 2016-001378-13 A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia. Eine randomisierte, sham-kontrollierte Vergleichsstudie von tiefer Hirnstim... not-yet-due
Ongoing 2016-004446-29 Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients not-yet-due
Other 2017-001616-11 Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequ... not-yet-due
Ongoing 2018-001802-27 A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma. Eine multizentrische, offene Phase I... not-yet-due
Reported results Terminated 2018-002849-11 Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation 2021-06-16 due-trials
Exempt 2019-001264-30 A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma not-yet-due
Not reported 2019-003190-26 An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER Eine Prüfarzt-initiierte offe... 2022-11-25 due-trials
Ongoing 2022-001041-20 Prednisolone and vitamin B1, B6, and B12 in patients with Post-COVID-19-Syndrome (PC19S) – a randomized controlled trial in primary care Prednisolon und Vitamin B1, B6 und B12 für Patient/innen mit... not-yet-due
Other 2022-001201-48 Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC) Sequenzielle oder frühzeitige dreifach-T... not-yet-due